New radiation treatment significantly increases survival rate

October 16, 2012

A novel drug that mimics a naturally occurring molecule found in coffee and blueberries has been developed to treat radiation exposure. Charles R. Yates, Pharm.D., Ph.D., and colleagues Duane Miller, Ph.D., and Waleed Gaber, Ph.D., from the University of Tennessee Health Science Center and Baylor College of Medicine, show that application of this drug, starting 24 hours after radiation exposure, increases survival in animal models by three-fold compared to placebo.

Their work, which is funded through an NIH grant from the National Institute for Allergy and Infectious Diseases, is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Chicago, Ill., Oct. 14 – 18.

"Development of drugs for individuals who are exposed to high- in a has been a priority since the 9/11 terrorist attacks," said Yates. "The ultimate goal is wide dissemination of non-invasive treatments after 24 hours of a mass casualty."

The high risk of vomiting after proves problematic for oral treatments, the most common non-invasive delivery method. Injectable medication is often proposed as the next line of defense, which comes with its own challenges. For example, training is often required for injections. To combat this problem, Yates and his team designed a new delivery system that can be applied directly to the skin, similar to an adhesive bandage.

"We are extremely proud to have exclusive rights to this exciting technology," said W. Shannon McCool, D.Ph., president & CEO of RxBio, the entity that has licensed the technology from the University of Tennessee Research Foundation.

This drug is also highly effective in models where radiation exposure is combined with skin wounds – a likely scenario in which people are exposed to shrapnel from dirty bombs or associated burn wounds.

Explore further: Innovative transdermal patch for delivery of HIV medicine featured at AAPS Annual Meeting

Related Stories

Innovative transdermal patch for delivery of HIV medicine featured at AAPS Annual Meeting

October 25, 2011
An innovative delivery method for human immunodeficiency virus (HIV) medications has been developed through use of a transdermal patch, the first of its kind to treat HIV. This research is being presented at the 2011 American ...

Novel biomarkers reveal evidence of radiation exposure

May 22, 2012
Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for ...

Researchers successfully treat previously lethal doses of radiation

January 5, 2012
Multiple scenarios exist where warfighters may be exposed to high levels of radiation. Countermeasures against possible high doses of radiation are an ongoing high priority for Department of Defense research and development ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.